# Eli Lilly and Company (LLY)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/LLY/primer

## Business Model

---
ticker: LLY
step: 01
generated: 2026-05-11
source: quick-research
---

### Eli Lilly and Company (LLY) — Business Overview

#### Business Description
Eli Lilly is a US-based global pharmaceutical company that has emerged as the dominant force in the incretin (GLP-1 / GIP) class for diabetes and obesity treatment. Its tirzepatide franchise — marketed as Mounjaro (diabetes) and Zepbound (obesity) — has reshaped both the company and the broader cardiometabolic drug market. Beyond cardiometabolic, Lilly is a significant player in oncology, immunology, and Alzheimer's disease, with Kisunla (donanemab) approved for early symptomatic Alzheimer's.

#### Revenue Model
- **Branded pharmaceutical sales (~98% of revenue):** Direct sales to pharmacies, hospitals, and PBMs in the US, plus international sales (mostly through subsidiaries). Key franchises include the tirzepatide twins (Mounjaro / Zepbound), Verzenio (oncology), Taltz (immunology), Trulicity (legacy diabetes), Jardiance (diabetes, partnered with Boehringer Ingelheim), Kisunla (Alzheimer's), and Ebglyss (atopic dermatitis).
- **Royalty & collaboration income:** Partnerships including Boehringer Ingelheim on Jardiance.
- **Direct-to-consumer cash-pay:** LillyDirect platform sells Zepbound vials directly to self-pay consumers in the US — a structurally important channel that bypasses PBM rebates.

Pricing is largely list-minus-rebate in the US, with growing direct cash-pay share for obesity. International pricing is materially lower; volume is the constraint, not demand.

#### Products & Services
- **Mounjaro (tirzepatide)** — Type 2 diabetes (largest franchise, $7.4B in Q4 2025 alone, +110% YoY)
- **Zepbound (tirzepatide)** — Obesity (US Q4 2025 revenue $4.2B, +122% YoY)
- **Trulicity (dulaglutide)** — Legacy GLP-1, declining as Mounjaro cannibalizes
- **Verzenio (abemaciclib)** — Breast cancer
- **Taltz (ixekizumab)** — Psoriasis / psoriatic arthritis / axial spondyloarthritis
- **Jardiance (empagliflozin)** — Diabetes (BI-partnered)
- **Kisunla (donanemab)** — Early symptomatic Alzheimer's
- **Ebglyss (lebrikizumab)** — Atopic dermatitis
- **Pipeline:** orforglipron (oral GLP-1, Phase 3 / regulatory submitted), retatrutide (triple agonist), eloralintide, MK-0616 partnership (PCSK9), multiple oncology and Alzheimer's candidates

#### Customer Base & Go-to-Market
- **US (~70% of revenue):** Sold through PBMs, retail pharmacies, hospitals, and increasingly direct via LillyDirect. Heavy DTC marketing for Zepbound.
- **International (~30% and growing fast):** Direct sales subsidiaries in Europe, China, Japan, Latin America; international Zepbound/Mounjaro launches accelerating as manufacturing capacity comes online.
- **Hospital and specialty channel:** For oncology (Verzenio), immunology (Taltz), and Alzheimer's (Kisunla, infused).
- **Payer mix:** Commercial insurance, Medicare Part D, Medicaid (heavy rebate exposure), and a fast-growing cash-pay segment.

No single customer represents material concentration; the principal demand-side risk is payer coverage for obesity (Medicare, employer plans).

#### Competitive Position
Lilly has decisively taken the lead in the incretin class, capturing ~57% of the GLP-1 / GIP market by Q2 2025 (up from ~53% earlier in the year), with Novo Nordisk losing share for the first time. The moat sources are: (1) **efficacy** — tirzepatide delivers ~20% body weight reduction vs. ~14% for semaglutide; (2) **manufacturing scale** — Lilly has committed >$50B in US capex (Alabama, Pennsylvania, North Carolina, Europe) and produced 1.6x more salable doses in H1 2025 vs. H1 2024; (3) **pipeline depth** — orforglipron (oral GLP-1) outperformed oral semaglutide head-to-head and is submitted for approval, retatrutide is the next-generation triple agonist; (4) **diversification** — oncology, immunology, and Alzheimer's franchises provide non-GLP-1 revenue, unlike Novo's narrower portfolio. Key risks: payer pushback on obesity pricing, MFN executive order pricing pressure, compounded GLP-1 competition (largely curtailed), and longer-term obesity competition from Pfizer, Roche, Amgen, and Viking.

#### Key Facts
- Founded: 1876
- Headquarters: Indianapolis, IN
- Employees: ~47,000
- Exchange: NYSE
- Sector / Industry: Health Care / Pharmaceuticals
- Market Cap: ~$700B (May 2026)

## Financial Snapshot

---
ticker: LLY
step: 04
generated: 2026-05-11
source: quick-research
---

### Eli Lilly and Company (LLY) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | YoY (25v24) |
|--------|--------|--------|--------|--------|-------------|
| Revenue | $28.5B | $34.1B | $45.0B | $65.2B | +44.7% |
| Gross Margin | ~75% | ~80% | ~81% | ~83% | +200 bps |
| Operating Margin | 23% | 17% | 32% | ~39% | +700 bps |
| Net Income | $6.2B | $5.2B | $10.6B | ~$22B | +108% |
| EPS (diluted) | $6.90 | $5.80 | $11.71 | ~$24.50 | +109% |

Note: FY2023 net income / margin compressed due to large in-process R&D writedowns from the Versanis and POINT Biopharma acquisitions; FY2024 expanded materially as those one-time charges rolled off and tirzepatide ramped.

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$15B |
| Capex | ~$11B (heavy manufacturing buildout) |
| Free Cash Flow | ~$4B (constrained by capex) |
| Cash & Investments | ~$5B |
| Total Debt | ~$33B |
| Net Debt | ~+$28B |

#### Key Ratios (approximate, May 2026)
- P/E: ~28x | EV/EBITDA: ~25x | FCF Yield: ~0.7% (suppressed by capex)
- Revenue Growth (TTM): ~45% | Gross Margin: ~83% | Operating Margin: ~39%
- Capex / Revenue: ~17% — Lilly is in the steepest manufacturing build cycle in big-pharma history

#### Growth Profile
Lilly has gone from ~$28B in revenue in 2022 to ~$65B in 2025 — a roughly 2.3x expansion in three years, almost entirely driven by the tirzepatide franchise (Mounjaro + Zepbound combined run-rate >$45B by end of 2025). The constraint has been supply, not demand: Lilly produced 1.6x more salable doses in H1 2025 vs. H1 2024. Operating leverage is now compounding meaningfully — gross margin remains in the low-80s and operating margin has expanded from 17% (2023, depressed by IPR&D charges) to ~39% (2025). Free cash flow is structurally suppressed by the $50B+ multi-year US manufacturing capex program.

#### Forward Estimates
**2026 guidance (issued Feb 2026): Revenue $80–83B (+25% YoY)**. Consensus FY2026 EPS: ~$31. Bull-side scenarios pencil in 2027 revenue >$100B if orforglipron (oral GLP-1) launches strongly in H2 2026 and Zepbound DTC volumes ramp. Bear-side scenarios bake in MFN pricing pressure on US obesity prices, slower-than-expected payer expansion, and 2030+ generic erosion of tirzepatide.

## Recent Catalysts

---
ticker: LLY
step: 12
generated: 2026-05-11
source: quick-research
---

### Eli Lilly and Company (LLY) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Orforglipron oral GLP-1 approval (mid-April 2026 PDUFA)** — Phase 3 data showed 12–15% weight loss and head-to-head superiority vs. oral semaglutide. A US approval opens a structurally new market: needle-phobic patients, easier global distribution, and a much lower cost-to-manufacture profile than injectables. Bull-case incremental peak revenue estimates range $15–30B and would expand obesity TAM by 2–3x.

2. **Retatrutide triple-agonist data readouts through 2026** — Phase 3 TRANSCEND-T2D-1 results at ADA in June 2026, with broader Phase 3 obesity readouts later in the year. Mid-cycle data has shown weight loss up to ~29% (vs. ~22% for tirzepatide), positioning retatrutide as the next-generation obesity gold standard for the late-2020s — and a structural pipeline answer to eventual tirzepatide patent expiry.

3. **Mounjaro + Zepbound continuing to take share at scale** — Lilly now holds ~57% of the GLP-1 / GIP market (up from ~53% in early 2025). Q1 2026 print delivered Mounjaro $8.66B (+125% YoY) and Zepbound $4.16B (+80% YoY) with total revenue growth of 56%. Sell-side has raised 2026 guidance and several analysts now model peak combined tirzepatide revenue >$70B by 2030.

4. **Manufacturing capacity finally meeting demand** — Lilly's $50B+ US capex program (Alabama, Pennsylvania, North Carolina, Europe) is unlocking 1.6x+ production growth and removing the volume cap that has constrained reported revenue. Supply elasticity is unlocking international launches (LATAM, Asia-Pacific, EU expansion) and the LillyDirect cash-pay channel.

#### Bear Case Risks

1. **Most Favored Nation (MFN) drug pricing risk** — Executive-order-driven pressure to reference-price US drugs to OECD averages would compress US tirzepatide net pricing by 30–50%. Even non-binding MFN frameworks have already contributed to a 13% realized price decline globally (-25% ex-US) in 2025. If codified into law or Medicare negotiation mechanics, US net pricing could compress materially through 2026–2028.

2. **GLP-1 competition intensifying** — Novo Nordisk is launching oral Wegovy globally, Pfizer (danuglipron successor), Roche (CT-388/996), Amgen (MariTide), and Viking Therapeutics (VK2735) all have Phase 2/3 obesity programs targeting 2027–2028 launches. The leadership window is real but not permanent; any safety signal on tirzepatide (e.g., FDA reporting on liver failure earlier in 2026 caused a sharp swing) could compress share.

3. **Tirzepatide patent cliff in 2036** — Composition-of-matter expires 2036; biosimilar / generic erosion modeling typically prices in 50–70% sales decline over 3 years post-LOE. While follow-on patents and retatrutide should partially bridge, the long-duration earnings risk is real and underweighted in current consensus models.

4. **Concentration risk + execution risk on capacity** — Tirzepatide franchise represents >65% of Lilly's revenue. Any manufacturing setback (recall, supply chain disruption, FDA inspection findings) hits the entire growth thesis. Capex is running at ~17% of revenue — uncommonly high for big pharma — and any execution miss compresses returns on invested capital.

#### Upcoming Events
- **Mid-April 2026**: Orforglipron PDUFA decision (US oral GLP-1 approval)
- **June 2026**: Retatrutide TRANSCEND-T2D-1 Phase 3 data at ADA Scientific Sessions
- **Q2 2026 earnings**: Early August 2026
- **H2 2026**: Retatrutide Phase 3 obesity readouts; potential FDA filing
- **2026**: Multiple label expansions (Zepbound for sleep apnea, MASH, etc.)
- **Q3 2026 earnings**: Late October 2026

#### Analyst Sentiment
Sell-side consensus skews Buy / Strong Buy (~85% positive). Average 12-month price targets cluster around $1,000–$1,250 (vs. current trading near $850–$900). Barclays raised PT to $1,400 in May 2026 citing tirzepatide momentum. The principal divergence is between near-term price-erosion bears (modeling MFN + payer pressure) and pipeline bulls (modeling orforglipron + retatrutide bridging tirzepatide).

#### Research Date
Generated: 2026-05-11

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/lly
- Full research API: GET /api/v1/research/LLY/memo
- Coverage universe: /stocks